We are pleased to share data demonstrating barzolvolimab profoundly improves #angioedema, the swelling of the deeper dermal layers of the skin and mucous membranes, at 52 weeks in the Phase 2 clinical trial in #CSU. Learn more below & here: https://t.co/osYt181e1w #EAACI2025

We were pleased to present new data at #EAACI2025 demonstrating profound, sustained complete response & improved quality of life at 76 weeks—7 months post-dosing with barzolvolimab in #CSU. Find details & listen to the playback of our recent webcast here. https://t.co/gJUbYWihh8

Thanks to the community engagement efforts of Celldex team member Jesse Hall, we recently welcomed @BristolCC biology students & their Dean of #STEM to our Fall River branch. We appreciate opportunities to introduce students to summer internships across departments at Celldex!

Last week, we enjoyed a paint night organized by our Fall River Wellness Committee. We were lucky to have a warm, sunny day and enjoyed designing flower pots out by the water. It was a perfect evening to welcome spring with our teammates!🎨

Our Fall River team was excited to welcome @stonehill_info chemistry students to our office to learn about careers in #biotech. Team members guided students through a “day in the life," explaining their roles, key responsibilities & exciting aspects of working in biotech. 🔬

We're excited to welcome Clinical Data Manager Meghan O'Neil to Celldex! From the lab bench to clinical trials coordination, Meghan adds valuable perspective to our team. Read more about her below.

We are pleased to present positive data on measurements of disease control & quality of life from the Phase 2 barzolvolimab studies in patients with chronic #urticaria at #AAAAI25. Find details on this milestone for Celldex & those living with CSU/CIndU: https://t.co/CCs2bAwx97

We're grateful for the chance to reflect, appreciate our teammates and give back to our communities this holiday season. We recently held holiday get-togethers and gift drives in our offices, which allowed us to donate a variety of items to help local families in need. ❄️

This weekend, we presented positive results from the Phase 2 clinical trial of barzolvolimab in 2 of the most common forms of chronic inducible #urticaria, cold urticaria and symptomatic dermographism, at #ACAAI24. More from CMO Diane Young below. Details: https://t.co/2GauLikpF9

It felt like the perfect fall weather at our annual fall cornhole tournament and BBQ at our Fall River office last week! To complement the chilly yet sunny day, we had warm apple cider and apple crumble along with our traditional BBQ lunch.🍁

It took 3+ years and multiple healthcare providers for Head of Medical Affairs Suki Bagal to receive her diagnosis of both #CSU and #ColdU. In part 2 of her story, Suki takes us through her journey to diagnosis & the impact working at Celldex has had on her life. #UDAY2024

When Head of Medical Affairs Suki Bagal works with physicians & patients, she relates to them on a level many others cannot: she, too, lives with urticaria and understands how life-altering this disease can be. In honor of #UDAY2024, this is part one of Suki's story.

Tomorrow is #UDAY2024! Every member of the Celldex team, from research to HR, is dedicated to advancing our mission of delivering new therapies for inflammatory diseases like urticaria. We are getting ready to honor the millions affected by urticaria at Celldex tomorrow.

We are gearing up for #UDAY2024 next week. Each year, Urticaria Day aims to raise awareness of chronic #urticaria and advocate for new, improved treatment options for the millions of patients worldwide who live with this condition. Learn more about #UDAY2024 from @ACARE_UCARE.

We're excited to present landmark 52 week results from the Phase 2 study of barzolvolimab in CSU. The data were presented @ the #EADVCongress by Dr. Martin Metz today. Listen below as he shares what he believes makes these data exciting for patients. More: https://t.co/mewXM6LvO0

We're excited to introduce our #Talent Community: a place for prospective candidates to stay connected to our team so that you can be notified about career opportunities, company news and events we will be attending. Sign up is easy - click here to join.

Dr. Marcus Maurer was a champion for urticaria research and a deeply dedicated advocate for new treatments to improve the lives of patients. It is with heavy hearts we share a statement from CEO Anthony Marucci on the news of his passing.

As the summer games come to a close, we channelled our inner athletes in our Fall River office for some friendly competition! Team members battled it out in the water balloon pass, "gown up" race and "potato between the leg" race. Next stop, Paris!

KIT expression is critical to the activity of #mastcells. Our #antibody therapeutic approach has been built on KIT inhibition to shut down harmful mast cells. Listen into why we believe this could be transformative for patients in the final episode of Talking with Tibor.

Mast cells play a key role in #allergy and inflammatory diseases, and are responsible for many harmful symptoms that patients with these disease experience. In part 2 of Talking with Tibor, we dive into what a #mastcell is, and where they get their infamous reputation from.